Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 3 of 3
Full-Text Articles in Entire DC Network
Novartis's Alex Gorsky: Ensuring That Patients Get Access To The Medicines They Need, Knowledge@Smu
Novartis's Alex Gorsky: Ensuring That Patients Get Access To The Medicines They Need, Knowledge@Smu
Knowledge@SMU
Alex Gorsky was named head of Pharma North America and CEO of Novartis Pharmaceuticals Corp., the U.S. affiliate of Swiss drug giant Novartis, in the fall of 2005. Since joining the company in 2004 as chief operating officer and head of general medicines, Gorsky has overseen the continued growth of Novartis's industry-leading cardiovascular franchise, notably the blockbuster drugs Diovan and Lotrel. The company sells a variety of products, including those that treat endocrine and respiratory disease, gastrointestinal illnesses, cancer and blood disorders and bone and joint conditions, among others. Prior to joining Novartis, Gorsky was company group chairman for Johnson …
Can't Afford To See A Doctor? The Difficulties Of Reforming China's Healthcare System, Knowledge@Smu
Can't Afford To See A Doctor? The Difficulties Of Reforming China's Healthcare System, Knowledge@Smu
Knowledge@SMU
An article co-published on May 22 by China Social Science Literature Publishing house and China Medical Industry Magazine, entitled “Healthcare Greenpaper,” reviews a series of problems associated with China’s healthcare reform over the past 10 years. Of the five biggest problems identified by the paper, the worst one is prohibitively expensive treatment. To examine this issue, Knowledge@Wharton interviewed a variety of experts and officials on the state of health care in China and the changing relationships between hospitals and patients.
Industry Leaders Debate Big Pharma R&D (Too Little Hope?) And Stem Cell Research (Too Much Hype?), Knowledge@Smu
Industry Leaders Debate Big Pharma R&D (Too Little Hope?) And Stem Cell Research (Too Much Hype?), Knowledge@Smu
Knowledge@SMU
Different points on the research spectrum were under the microscope at the Wharton Health Care Business Conference last month as two panels of biotech, pharmaceutical and investment leaders discussed the state of R&D among big pharmaceuticals and the progress of stem cell research. While disappointing results in both sectors have dominated the news lately, panelists at each session also noted some promising developments -- and causes for optimism -- in their respective fields.